XML 13 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 407,368 $ 376,689 [1]
Marketable securities 34,122 51,580 [1]
Investment in equity securities 49,803 43,653 [1]
Receivable from licensing and collaboration agreements 10,761 17,079 [1]
Restricted cash 25,503 37,930 [1]
Prepaid expenses and other current assets 25,145 21,922 [1]
Total current assets 552,702 548,853 [1]
Property and equipment, net 13,566 14,569 [1]
Operating lease right-of-use assets 10,532 10,678 [1]
Intangible assets, net 28,113 28,712 [1]
Other assets 20,767 20,224 [1]
Total assets 625,680 623,036 [1]
Current liabilities:    
Accounts payable 4,076 11,558 [1]
Accrued compensation and benefits 18,869 31,256 [1]
Accrued research and development liabilities 37,064 39,803 [1]
Accrued professional services 4,015 1,790 [1]
Operating lease liabilities, current portion 3,674 3,675 [1]
Deferred revenue, current portion 6,675 8,156 [1]
Other accrued liabilities 22,223 25,190 [1]
Total current liabilities 96,596 121,428 [1]
Term loan, net 435,764 430,993 [1]
Operating lease liabilities, net of current portion 11,904 12,274 [1]
Other long-term liabilities 17,501 26,643 [1]
Total liabilities 1,839,293 1,867,960 [1]
Commitments and contingencies (Note 8)
Redeemable convertible noncontrolling interests (204) (1,589)
Stockholders’ equity (deficit):    
Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 500,000,000 shares authorized;166,626,999 shares issued and 160,435,238 shares outstanding as of March 31, 2023, 156,817,333 shares issued and 150,625,572 shares outstanding as of December 31, 2022 167 157 [1]
Treasury stock, at cost; 6,191,761 shares as of March 31, 2023 and December 31, 2022 (275,000) (275,000) [1]
Additional paid-in capital 1,106,635 938,703 [1]
Accumulated other comprehensive loss (12) (328) [1]
Accumulated deficit (2,057,455) (1,918,149) [1]
Total BridgeBio stockholders' deficit (1,225,665) (1,254,617) [1]
Noncontrolling interests 12,256 11,282 [1]
Total stockholders' deficit (1,213,409) (1,243,335) [1],[2]
Total liabilities, redeemable convertible noncontrolling interests and stockholders' deficit 625,680 623,036 [1]
2029 Notes    
Current liabilities:    
Notes, net 735,463 734,988 [1]
2027 Notes    
Current liabilities:    
Notes, net $ 542,065 $ 541,634 [1]
[1] The condensed consolidated balance sheet as of December 31, 2022 is derived from the audited consolidated financial statements as of that date.
[2] The consolidated balances as of December 31, 2022 and 2021 are derived from the audited consolidated financial statements as of those dates.